These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Drug marketing exclusivity under United States and European Union law. Junod V Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347 [No Abstract] [Full Text] [Related]
3. FDA to steer nanotech. Fox JL Nat Biotechnol; 2008 Oct; 26(10):1060. PubMed ID: 18846060 [No Abstract] [Full Text] [Related]
4. Trouble at the office. Allison M Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797 [No Abstract] [Full Text] [Related]
5. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration? Zelenay JL Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773 [No Abstract] [Full Text] [Related]
6. The Prescription Drug User Fee Act of 1992: speeding up the drug approval process. Bierut MB Healthspan; 1992 Dec; 9(11):12-4. PubMed ID: 10123552 [No Abstract] [Full Text] [Related]
7. The FDA and "privatization"--the drug approval process. Rutherford EM Food Drug Law J; 1995; 50 Spec():203-25. PubMed ID: 10343044 [No Abstract] [Full Text] [Related]
8. Bush tails follow-ons. Fox J Nat Biotechnol; 2008 Apr; 26(4):366. PubMed ID: 18392007 [No Abstract] [Full Text] [Related]
9. A precarious balancing act--the role of the FDA as protector of public health and industry wealth. McCabe AR Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844 [No Abstract] [Full Text] [Related]
10. TransMolecular receives FDA approval for 131-I-TM-601 IND application. Expert Rev Anticancer Ther; 2002 Apr; 2(2):139. PubMed ID: 12113233 [No Abstract] [Full Text] [Related]
11. Dismissal of investor fraud claim over HIV drug reversed. AIDS Policy Law; 2008 Nov; 23(12):8. PubMed ID: 19145698 [No Abstract] [Full Text] [Related]
12. Summary Basis of Decision in context. Gorman D CMAJ; 2005 Jun; 172(13):1664; author reply 1664-5. PubMed ID: 15967953 [No Abstract] [Full Text] [Related]
13. HHS: POUFA reauthorization good for Americans. FDA Consum; 2002; 36(5):5. PubMed ID: 12412536 [No Abstract] [Full Text] [Related]
15. Remarks at the Food and Drug Law Institute's 48th Annual Conference. Niedelman SM Food Drug Law J; 2005; 60(2):117-26. PubMed ID: 16097089 [No Abstract] [Full Text] [Related]
16. Pros and cons of off-label promotion investigations and prosecutions. Loucks MK Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041 [No Abstract] [Full Text] [Related]
17. Regulatory watch: impact of PDUFA on regulatory decision-making. Hay M Nat Rev Drug Discov; 2010 Aug; 9(8):585. PubMed ID: 20671755 [No Abstract] [Full Text] [Related]
18. Remember the Little Red Hen? Pearson K Altern Med Rev; 1998 Dec; 3(6):409. PubMed ID: 9855565 [No Abstract] [Full Text] [Related]
19. FDA attempting to overcome major roadblocks in monitoring drug safety. Zielinski SL J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645 [No Abstract] [Full Text] [Related]